Final clinical and pharmacokinetic (PK) results from a phase 1 study of the novel N-cadherin (N-cad) antagonist, Exherin (ADH-1), in patients with refractory solid tumors stratified according to N-cad expression
David J. Stewart(University of Ottawa), W. P. Peters(Duke University), William A. Wargin(Ottawa Hospital), Derek J. Jonker(University of Ottawa), C. Cripps(Canadian Partnership Against Cancer), J. Maroun, Glenwood D. Goss(Ontario Institute for Cancer Research), R. K. Malik(Ottawa Hospital), Julie Wells(Ottawa Hospital), Rakesh Goel(Ottawa Hospital)
Cited by 14
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer
|Journal of Clinical Oncology|1999|960
Wnt Signaling Pathway in Non-Small Cell Lung Cancer
|JNCI Journal of the National Cancer Institute|2013|659